BioCentury
ARTICLE | Clinical News

Brovana: Phase III data

December 9, 2013 8:00 AM UTC

Dainippon's Sunovion Pharmaceuticals Inc. subsidiary reported data from a double-blind, U.S. Phase III trial in 841 patients with moderate to severe COPD showing that twice-daily 15 µg Brovana met the...